FDA Approves Hibsago for Chronic Hepatitis B Treatment

Learn about the FDA approval of Hibsago (bepirovirsen), its clinical trial results, potential functional cure rates, eligibility criteria, and safety information.

Introduction

The treatment landscape for chronic hepatitis B has reached an important milestone following the US Food and Drug Administration's (FDA) approval of Hibsago (bepirovirsen), a new treatment option for eligible adults living with chronic hepatitis B virus (HBV) infection. Announced by GSK on October 20, 2026, the approval introduces an innovative approach that may help some patients achieve a functional cure after a six-month treatment course.

Chronic hepatitis B remains a significant global health concern because it can cause long-term liver damage and increase the risk of serious complications, including liver cancer. Although existing antiviral medicines can effectively suppress the virus, many patients need to continue treatment indefinitely.

Hibsago offers a potential new direction by targeting the viral components responsible for maintaining infection. However, its benefits depend on patient eligibility, and a functional cure is not guaranteed for everyone.

What Is Hibsago (Bepirovirsen)?

Hibsago, also known as bepirovirsen, is an antisense oligonucleotide (ASO) developed to reduce the production of hepatitis B viral components. It works by targeting viral RNA, which plays an important role in producing proteins associated with HBV infection.

By reducing viral RNA and hepatitis B surface antigen (HBsAg) levels in the blood, bepirovirsen may help the immune system regain better control over the infection.

Unlike conventional antiviral treatments that primarily suppress viral replication, this approach aims to achieve a more sustained response that may continue after treatment ends.

According to GSK, Hibsago is approved in the United States in combination with nucleos(t)ide analogue reverse transcriptase inhibitor therapy for a specific group of adults with chronic hepatitis B.

Who Is Eligible for Hibsago Treatment?

The FDA approval applies to adults who meet specific clinical criteria. According to the announcement, eligible patients must:

• Have chronic hepatitis B virus infection.
• Be receiving nucleos(t)ide analogue therapy for at least six months.
• Have suppressed HBV DNA levels.
• Have hepatitis B surface antigen levels of 3,000 IU/mL or lower, confirmed using an FDA-authorised test.
• Have no cirrhosis.

Hibsago is used alongside existing nucleos(t)ide analogue therapy rather than as a replacement for it during the approved treatment regimen.

Doctors will need to evaluate patients' medical histories, liver health, viral markers, and treatment responses before determining whether Hibsago is appropriate.

Quantitative HBsAg testing is particularly important because it helps identify patients who meet the treatment criteria.

Clinical Trial Results Show Potential for Functional Cure

The FDA approval was supported by results from the B-WELL 1 and B-WELL 2 Phase III clinical trials. These international studies evaluated bepirovirsen in adults with chronic hepatitis B who were already receiving nucleos(t)ide analogue therapy.

Pooled results showed that 19% of participants receiving bepirovirsen achieved a functional cure, compared with none in the pooled placebo group. The treatment group included 233 of 1,220 participants, while the placebo group included 614 participants.

Among participants whose baseline HBsAg levels were 1,000 IU/mL or lower, the functional cure rate reached 26%. This represented 200 of 768 participants, compared with none of the 393 participants in the corresponding placebo group.

These findings suggest that baseline HBsAg levels may help identify patients who have a greater likelihood of benefiting from treatment.

The results are encouraging, but they also highlight an important limitation: most participants did not achieve a functional cure during the reported assessment period.

What Does Functional Cure Mean?

A functional cure for chronic hepatitis B does not necessarily mean that every trace of the virus has been eliminated from the body.

In the context described in the clinical trial announcement, functional cure means that HBV DNA and hepatitis B surface antigen remain undetectable for at least 24 weeks after all treatment has been discontinued.

This outcome indicates that the immune system can maintain control over the infection without ongoing medication during that period.

Achieving a functional cure is an important goal in hepatitis B research because many patients currently depend on long-term antiviral therapy to suppress the virus.

Nevertheless, patients should continue medical follow-up even after achieving a functional cure, as their doctors may recommend monitoring for viral recurrence and liver-related complications.

How Long Does Hibsago Treatment Last?

According to GSK's announcement, the Hibsago treatment course lasts six months. The company also reported that patients may have the option of self-administration after the first dose.

This could offer greater convenience for suitable patients, depending on the prescribed regimen and their healthcare provider's instructions.

The possibility of completing a defined treatment course is particularly significant for people who have spent years managing chronic hepatitis B with ongoing medication.

However, treatment duration and administration arrangements should always follow the approved prescribing information and a healthcare professional's guidance.

Safety and Possible Side Effects

The B-WELL Phase III trials reported an acceptable safety and tolerability profile consistent with previous studies of bepirovirsen.

The most frequently reported adverse events included:

• Redness at the injection site.
• Localised pain.
• Temporary increases in blood levels of a liver enzyme.

These findings provide useful information about the treatment's observed safety profile in clinical trials. However, individual experiences may differ, and the reported adverse events do not represent every possible risk.

Patients should discuss existing medical conditions, other medications, potential side effects, and monitoring requirements with their healthcare providers before beginning treatment.

Anyone experiencing concerning symptoms during treatment should contact their medical team promptly.

Why This Approval Matters for Chronic Hepatitis B

Chronic hepatitis B affects millions of people worldwide and remains an important cause of liver disease and liver cancer.

Current antiviral medicines can control viral replication, but long-term management often requires ongoing treatment. As a result, researchers have focused on developing therapies that may help patients achieve sustained control without continuous medication.

Hibsago represents progress towards that goal by introducing an antisense oligonucleotide treatment designed to target viral RNA.

Its clinical trial results demonstrate that functional cure may be achievable for a proportion of appropriately selected patients. Further research and real-world experience will help clarify its long-term benefits, safety, and role in routine clinical practice.

GSK has also reported continuing regulatory submissions in other regions, indicating that access and approval status may differ between countries.

Conclusion

The FDA approval of Hibsago (bepirovirsen) marks an important development in chronic hepatitis B treatment. Supported by Phase III B-WELL trial results, the medicine offers eligible adults the possibility of achieving a functional cure following a six-month treatment course.

The reported 19% functional cure rate across the overall study population, rising to 26% among participants with lower baseline HBsAg levels, provides encouraging evidence of its potential.

However, Hibsago is not a guaranteed cure, and most participants did not achieve the defined functional cure outcome. Careful patient selection, appropriate monitoring, and continued medical supervision remain essential.

For people living with chronic hepatitis B, this approval represents a meaningful advance in treatment research and offers another potential option to discuss with a qualified healthcare professional.

Source: GSK plc, company announcement dated October 20, 2026, covering the FDA approval of Hibsago, B-WELL Phase III clinical trial results, treatment eligibility, and safety information.

Medical Disclaimer

This article is intended for informational and educational purposes only and should not be considered medical advice, diagnosis, or a recommendation for treatment. Hibsago (bepirovirsen) should be used only by eligible patients under the supervision of a qualified healthcare professional and in accordance with the approved prescribing information. Treatment outcomes and side effects may vary between individuals. Do not stop or change existing hepatitis B medication without consulting your doctor. Always seek personalised medical advice for questions about hepatitis B diagnosis, treatment, and ongoing liver health.